I en sammenlignende undersøgelse med børn fra 1- 11 år var forekomsterne af lokale og generelle symptomer i Ambirix gruppen ens med dem som sås for 3 dosis kombinationsvaccinen indeholdende 360 ELISA enheder af formalin inaktiveret hepatitis A virus og 10 microgram rekombinant hepatitis B overfladeantigen.
In a comparative trial in subjects aged 1-11 years, the incidences of local and general solicited symptoms in the Ambirix group were similar to those seen with the three-dose combined vaccine containing 360 ELISA Units of formalin inactivated hepatitis A virus and 10 micrograms of recombinant hepatitis B surface antigen.